Kancera AB and has launched a collaborative research effort with Mary Hendrix and her research group at The Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine.
Hendrix, president and scientific director of the Children’s Memorial Research Center, studies factors responsible for the development of breast and skin cancer that are prone to spread and difficult to treat. Under the collaboration, Hendrix and Kancera will combine strengths in disease mechanism R&D and product development to deliver novel therapies aimed at overcoming drug resistance and relapse in cancer.
“Our research team is excited about the opportunity to translate basic discoveries with Kancera AB to more effective cancer treatments, as well as establish early prognostic markers of cancer development and drug resistance,” says Hendrix.
”We are very pleased to join forces with Professor Hendrix and convinced that the collaboration presents a mutually rewarding opportunity to accelerate translation of key research discoveries into new efficient anti-cancer therapies,” says Thomas Olin, chief executive officer, Kancera.
Release Date: May 9, 2011